← All Global Health Solutions, INC filings

Global Health Solutions, INC 10-Q quarterly reports

Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.

NASDAQ
TTRX
Global Health Solutions, INC
10-Q: Turn Therapeutics Faces Financial Hurdles Amidst Development
Turn Therapeutics Inc. reports substantial net losses and an accumulated deficit, raising concerns about its going concern status, while advancing its GX-03 drug candidate.
NASDAQ
TTRX
Global Health Solutions, INC
10-Q: Turn Therapeutics Q1 2026 Financials: Increased Burn, New Debt Facility
Turn Therapeutics reports a net loss of $0.97 million for Q1 2026, with cash reserves projected to last into Q1 2027, alongside securing a $25 million debt facility.
NASDAQ
TTRX
Global Health Solutions, INC
10-Q: Turn Therapeutics Lists on Nasdaq, Raises Capital Amid Losses
Turn Therapeutics Inc. completed its Nasdaq direct listing and secured significant financing, but reported increased net losses and faces going concern doubts.